Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Fatal levofloxacin failure in treatment of a bacteremic patient infected with Streptococcus pneumoniae with a preexisting parC mutation.

Literature DB >> 18287316

Fatal levofloxacin failure in treatment of a bacteremic patient infected with Streptococcus pneumoniae with a preexisting parC mutation.

M de Cueto¹, J M Rodríguez, M J Soriano, L López-Cerero, J Venero, A Pascual.

Abstract

The fatal outcome of levofloxacin treatment in a patient with bacteremic pneumonia caused by Streptococcus pneumoniae with a preexisting parC mutation is reported. Failure was due to the emergence of a gyrA mutation after 4 days of therapy. Problems encountered in detecting first-step mutation isolates are discussed.

Entities: Chemical Disease Species

Mesh：

Substances：

Year: 2008 PMID： 18287316 PMCID： PMC2292950 DOI： 10.1128/JCM.02066-07

Source DB: PubMed Journal: J Clin Microbiol ISSN： 0095-1137 Impact factor: 5.948

17 in total

1. Guidelines for the management of adults with community-acquired pneumonia. Diagnosis, assessment of severity, antimicrobial therapy, and prevention.

Authors: M S Niederman; L A Mandell; A Anzueto; J B Bass; W A Broughton; G D Campbell; N Dean; T File; M J Fine; P A Gross; F Martinez; T J Marrie; J F Plouffe; J Ramirez; G A Sarosi; A Torres; R Wilson; V L Yu
Journal: Am J Respir Crit Care Med Date: 2001-06 Impact factor: 21.405

2. Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults.

Authors: Lionel A Mandell; Richard G Wunderink; Antonio Anzueto; John G Bartlett; G Douglas Campbell; Nathan C Dean; Scott F Dowell; Thomas M File; Daniel M Musher; Michael S Niederman; Antonio Torres; Cynthia G Whitney
Journal: Clin Infect Dis Date: 2007-03-01 Impact factor: 9.079

3. Activities of fluoroquinolones against Streptococcus pneumoniae type II topoisomerases purified as recombinant proteins.

Authors: I Morrissey; J George
Journal: Antimicrob Agents Chemother Date: 1999-11 Impact factor: 5.191

4. Antimicrobial susceptibilities of 1,684 Streptococcus pneumoniae and 2,039 Streptococcus pyogenes isolates and their ecological relationships: results of a 1-year (1998-1999) multicenter surveillance study in Spain.

Authors: E Pérez-Trallero; C Fernández-Mazarrasa; C García-Rey; E Bouza; L Aguilar; J García-de-Lomas; F Baquero
Journal: Antimicrob Agents Chemother Date: 2001-12 Impact factor: 5.191

5. Mutant prevention concentrations for single-step fluoroquinolone-resistant mutants of wild-type, efflux-positive, or ParC or GyrA mutation-containing Streptococcus pneumoniae isolates.

Authors: Heather J Smith; Michael Walters; Tamiko Hisanaga; George G Zhanel; Daryl J Hoban
Journal: Antimicrob Agents Chemother Date: 2004-10 Impact factor: 5.191

6. Activities of mutant prevention concentration-targeted moxifloxacin and levofloxacin against Streptococcus pneumoniae in an in vitro pharmacodynamic model.

Authors: George P Allen; Glenn W Kaatz; Michael J Rybak
Journal: Antimicrob Agents Chemother Date: 2003-08 Impact factor: 5.191

7. Quinolone resistance among pneumococci: therapeutic and diagnostic implications.

Authors: Donald E Low
Journal: Clin Infect Dis Date: 2004-05-15 Impact factor: 9.079

8. Fluoroquinolone resistance in penicillin-resistant Streptococcus pneumoniae clones, Spain.

Authors: Adela G de la Campa; Luz Balsalobre; Carmen Ardanuy; Asunción Fenoll; Emilio Pérez-Trallero; Josefina Liñares
Journal: Emerg Infect Dis Date: 2004-10 Impact factor: 6.883

9. Mutant selection window in levofloxacin and moxifloxacin treatments of experimental pneumococcal pneumonia in a rabbit model of human therapy.

Authors: Delphine Croisier; Manuel Etienne; Emilie Bergoin; Pierre-Emmanuel Charles; Catherine Lequeu; Lionel Piroth; Henri Portier; Pascal Chavanet
Journal: Antimicrob Agents Chemother Date: 2004-05 Impact factor: 5.191

10. Fluoroquinolone and macrolide treatment failure in pneumococcal pneumonia and selection of multidrug-resistant isolates.

Authors: Emilio Pérez-Trallero; José M Marimon; Luis Iglesias; Julián Larruskain
Journal: Emerg Infect Dis Date: 2003-09 Impact factor: 6.883

8 in total

Review 1. Clinical importance and epidemiology of quinolone resistance.

Authors: Eu Suk Kim; David C Hooper
Journal: Infect Chemother Date: 2014-12-29

2. In Vitro Activity of Lascufloxacin against Streptococcus pneumoniae with Mutations in the Quinolone Resistance-Determining Regions.

Authors: Mika Murata; Kosuke Kosai; Shunsuke Yamauchi; Daisuke Sasaki; Norihito Kaku; Naoki Uno; Yoshitomo Morinaga; Hiroo Hasegawa; Taiga Miyazaki; Koichi Izumikawa; Hiroshi Mukae; Katsunori Yanagihara
Journal: Antimicrob Agents Chemother Date: 2018-03-27 Impact factor: 5.191

3. Association of levofloxacin resistance with mortality in adult patients with invasive pneumococcal diseases: a post hoc analysis of a prospective cohort.

Authors: C-I Kang; J-H Song; S H Kim; D R Chung; K R Peck; V Thamlikitkul; H Wang; T M So; P-R Hsueh; R M Yasin; C C Carlos; P H Van; J Perera
Journal: Infection Date: 2012-07-22 Impact factor: 3.553